Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SeaStar Medical HoldingICU -3.68%32 Equity-to-Asset is 0.50 as of Jun. 2026. GuruFocus rates ICU with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,414 Biotechnology companies, SeaStar Medical Holding ranks worse than 66.83% on this metric.
SeaStar Medical Holding (NAS:ICU) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
SeaStar Medical Holding Equity-to-Asset Related Terms
SeaStar Medical Holding Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU vs INTS, GTBP, KALA: Equity-to-Asset Comparison
For the Biotechnology subindustry, SeaStar Medical Holding's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SeaStar Medical Holding Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where SeaStar Medical Holding's Equity-to-Asset falls into.
SeaStar Medical Holding Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
SeaStar Medical Holding's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SeaStar Medical Holding (ICU) has a Equity-to-Asset of 0.50 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on SeaStar Medical Holding and its competitors. According to the industry distribution chart, SeaStar Medical Holding ranks #945 out of 1414 companies in the Biotechnology industry, placing it in the top 66.8%.
Is SeaStar Medical Holding's Equity-to-Asset too high?
SeaStar Medical Holding's current Equity-to-Asset is 0.50. The Biotechnology industry median Equity-to-Asset is 0.68. SeaStar Medical Holding's value of 0.50 is 26.5% below this industry median. Based on the distribution chart, SeaStar Medical Holding ranks #945 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SeaStar Medical Holding has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does SeaStar Medical Holding's Equity-to-Asset compare to INTS and GTBP?
According to the Biotechnology industry distribution chart, SeaStar Medical Holding ranks #945 out of 1414 companies for Equity-to-Asset. This places SeaStar Medical Holding in the lower half of its industry. The industry median Equity-to-Asset is 0.68. SeaStar Medical Holding's value of 0.50 is 26.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SeaStar Medical Holding's current Equity-to-Asset of 0.50 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on SeaStar Medical Holding and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SeaStar Medical Holding's current Equity-to-Asset is 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SeaStar Medical Holding stock overvalued right now?
SeaStar Medical Holding (ICU) has a current Equity-to-Asset of 0.50. The current Equity-to-Asset is 0.50 and 26.5% below the Biotechnology industry median of 0.68. SeaStar Medical Holding's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For SeaStar Medical Holding (ICU), the current Equity-to-Asset is 0.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
32GF Score
Get the complete analysis for ICU
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICU has been successfully added to your 
